Outsourcing biopharma R&D to India
The trend of outsourcing to India for research and development is catching on fast. Over the last decade, worldwide pharmaceutical and biotechnology companies have made India their choice for a research destination. Initially R&D was inclined more towards developing products for the Indian marke...
| Main Author: | |
|---|---|
| Format: | eBook |
| Language: | Inglés |
| Published: |
Oxford ; New York :
Biohealthcare
2011.
|
| Edition: | 1st edition |
| Series: | Woodhead Publishing series in biomedicine,
no. 2 Woodhead Publishing Series in Biomedicine |
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009628236506719 |
Table of Contents:
- Cover; Woodhead Publishing Seriesin Biomedicine; Outsourcing biopharma R&D to India; Copyright; Contents; Acknowledgements; About the author; 1 Biopharma outsourcing in India: its evolution; 1.1 What is outsourcing?; 1.2 What is R&D?; 1.3 Organisational patterns in R&D outsourcing; 1.4 R&D outsourcing in the pharmaceutical industry; 1.5 India as the emerging hub of R&D outsourcing in the pharmaceutical industry; 1.6 Outsourcing models prevalent in India: cooperation models for outsourced services; 1.7 Key issues involved in outsourcing; Notes
- 2 India's core competitive advantage in R&D in the biopharma sector: the impetus for outsourcing2.1 Introduction; 2.2 Cost competitiveness; 2.3 Resources and skill; 2.4 The role of the government; 2.5 Conclusion; Notes; 3 Different modes of outsourcing biopharma R&D to India; 3.1 Indian companies involved in outsourcing activities; 3.2 Contract research services; 3.3 Contract manufacturing organisations; 3.4 Drug substance manufacturing; 3.5 Drug product manufacturing; 3.6 Process development; 3.7 Analytical methods and characterisation
- 3.8 Business models for contract manufacturing organisations3.9 Insights into outsourcing of product development and manufacture; 3.10 Clinical trials; 3.11 Advantages and disadvantages of doing clinical trials in India; 3.12 Active pharmaceutical ingredient and technology transfer; 3.13 Conclusions and implications; Notes; 4 The Indian regulatory environment: a historical perspective; 4.1 Indian Council for Medical Research; 4.2 Central Drugs Standard Control Organisation; 4.3 Department of Biotechnology; 4.4 National Pharmaceutical Pricing Authority; 4.5 Overview of the industry; Notes
- 5 Implications of the changing regulatory environment in India5.1 Introduction; 5.2 Capacity Building Programme: recent development5; 5.3 Clinical Trials Registry - India; 5.4 The Indian Society for Clinical Research; 5.5 Conclusion; Notes; 6 Creating contracts for outsourcing in the biopharma industry; 6.1 Biopharma outsourcing; 6.2 Preliminary documentation; 6.3 Drafting of the biopharma outsourcing agreement; 6.4 Specific considerations in different types of agreements; 6.5 Conclusion; Notes; 7 Environmental, health and safety guidelines and biopharma outsourcing: an Indian perspective
- 7.1 Introduction7.2 The environmental, health and safety guidelines; 7.3 EHS guidelines and India; 7.4 Challenges faced by Indian companies in EHS compliance; 7.5 Conclusion; Notes; 8 Certifications; 8.1 Introduction; 8.2 Certifications; 8.3 Manufacturing licence; 8.4 Good Manufacturing Practices; 8.5 No-Objection Certificate and Certificate of Origin; 8.6 Certificate of a Pharmaceutical Product; 8.7 Certifications for clinical trials; 8.8 International regulatory certifications; 8.9 Conclusion; Notes; 9 The need for due diligence of service providers; 9.1 Introduction
- 9.2 Sources utilised prior to due diligence
